Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Acute therapies continue to report strong growth compared to chronic ones.
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Subscribe To Our Newsletter & Stay Updated